Virbac Animal Health has launched CaniLeish, the first vaccine for canine leishmaniosis in the European Union.

Leishmaniosis is a vector-borne parasitic disease caused by infection with protozoa of the genus Leishmania (L infantum in Europe). Leishmaniosis is transmitted by the bite of infected sandflies. In south-western Europe 2.5 million dogs are believed to be infected1,2 with the parasite and the disease is spreading northwards,3 as more people travel with their dogs or import infected animals from endemic areas.4  So far preventative methods have been limited to reducing the habitat of sandflies, minimising the physical contact of dogs with sandflies and using insecticides on dogs (sprays, spot-ons, repellent-collars, etc).

According to Virbac, CaniLeish's ability to protect dogs was demonstrated in an experimental challenge study, where the benefit of vaccination was still evident after one year.5 In an extreme condition natural challenge trial lasting two years under environmental conditions rarely encountered in reality, 93% of dogs vaccinated with CaniLeish did not develop symptomatic leishmaniosis. CaniLeish provides a fourfold reduction in the risk of developing this fatal disease. 6 Its safety profile has been shown in laboratory testing and field trials.7 In addition, Virbac says it contains no whole parasites that could be virulent in any host.

David McGahie BVMS Bsc (VetSci) MRCVS, Medical Department Manager at Virbac SA, said: "The development of this vaccine is a key milestone in the battle against this challenging disease which is a major problem in many regions of the world. Although in the past it was considered a rather exotic disease here in the UK, the advent of the Pet Travel Scheme means it has become increasingly important as a problem for dogs which regularly travel abroad to endemic regions."

CaniLeish can be given to dogs as young as six months of age: the primary course consists of three injections given over six weeks. Dogs should be re-vaccinated annually, with a single dose administered one year after the third injection and annually thereafter.

References:

  1. Baneth G, KoutinasAF, Solano-Gallego L, et al. Canine leishmaniosis: new concepts and insights on an expanding zoonosis: part one. Trends Parasitology 2008; 24: 324-330
  2. Moreno J, Alvar J. Canine leishmaniasis: epidemiological risk and the experimental model. Trends Parasitol, 2002; 18 (9):399-405
  3. Maroli M, Rossi L, Baldelli R, et al. The northward spread of leishmaniasis in Italy: evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop. Med. Int. Health, 2008; 13: 256-264
  4. Shaw SE, Lerga AI, Williams S, et al. Review of exotic infectious diseases in small animals entering the United Kingdom from abroad diagnosed by PCR. Vet. Rec. 2003; 152: 176-177
  5. McGahie D.  CaniLeish®: Development of a new preventive tool. How do you produce a vaccine which really works? Proceedings of the symposium "Advanced management of Canine Leishmaniosis" Southern European Veterinary Congress 2011, Barcelona, pp 13,14
  6. Oliva G, Nieto J, Foglia Manzillo V, et al. Evidence for protection against active infection and disease progression in naïve dogs vaccinated with LiESP/QA-21 (CaniLeish®) exposed to two consecutive Leishmania infantum transmission seasons. Proceedings BSAVA/WSAVA/FECAVA congress 2012, Birmingham.
  7. McGahie D.  Results of safety trials with CaniLeish®. What can be expected?. Proceedings of the symposium "Advanced management of Canine Leishmaniosis" Southern European Veterinary Congress 2011, Barcelona, pp 15,16
  8. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis and treatment, and a proposed research and development agenda. The Lancet Infectious Diseases 2002; 2: 494-501
  9. Gramiccia M, Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. International Journal for Parasitology 2005; 35: 1169-1180

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.